RxDoctor Payments Data

Adolphus Bonar, MD

Endocrinology, Diabetes & Metabolism · Gastonia, NCNPI 1578559373

Payments from drug & device makers

$1,718in general payments, 2019–2025

Across 29 payments — averaging $59.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$274
  • Corcept Therapeutics$239
  • Amarin Pharma, Inc.$188
  • Amgen$181
  • BETA Bionics, Inc.$151
  • Boehringer Ingelheim$139
  • plus $546 from 10 others

What the payments were for

  • Food & beverage$1,69499%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,718 in reported general payments places this provider in the 50th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

See all endocrinology, diabetes & metabolism providers in North Carolina

Medicare billing

Part B allowed, 2024
$84,357
Medicare patients
308
Services billed
3,785

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
KorlymMifepristone39$1,563,322
OzempicSemaglutide747$888,914
MounjaroTirzepatide237$273,361
JardianceEmpagliflozin303$257,068
RybelsusSemaglutide119$149,596
TrulicityDulaglutide116$147,721
Tresiba Flextouch U-200Insulin Degludec108$96,355
Humalog Kwikpen U-200Insulin Lispro36$73,860
JanuviaSitagliptin Phosphate91$66,176
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/772$66,049
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog68$53,902
Humalog Kwikpen U-100Insulin Lispro180$53,144
Tresiba Flextouch U-100Insulin Degludec85$48,171
Repatha SureclickEvolocumab62$47,747
VascepaIcosapent Ethyl85$43,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Corcept TherapeuticsKorlym$239$1,563,32239 claims
Novo NordiskOzempic, Rybelsus$79$1,038,509866 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy$139$307,143373 claims
Esperion Therapeutics, Inc.Nexletol$65$9,82217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 232 endocrinology, diabetes & metabolism providers in North Carolina.

Other endocrinology, diabetes & metabolism in Gastonia

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →